CELC Celcuity Inc.

NASDAQ
$79.52

Celcuity Inc. (CELC) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $1.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.2% since its last earnings release on August 13, 2026.

Celcuity Missed Consensus Estimates
Thursday, August 13, 2026 · 4:06 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.45)
Rev est $2.34M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $88.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Celcuity Inc.

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.